FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2959661609> ?p ?o ?g. }

• W2959661609 endingPage "811" @default.
• W2959661609 startingPage "800" @default.
• W2959661609 abstract "Summary Background In pancreatic ductal adenocarcinoma (PDAC), the chemokine (C-C motif) ligand 2 (CCL2)/chemokine (C-C motif) receptor 2 (CCR2) axis plays a key role in immunosuppressive properties of the tumor microenvironment, patient prognosis, and chemoresistance. This phase Ib study assessed the effects of the orally administered CCR2 inhibitor PF-04136309 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic PDAC. Methods Patients received PF-04136309 twice daily (BID) continuously plus nab-paclitaxel (125 mg/m 2 ) and gemcitabine (1000 mg/m 2 ) administered on days 1, 8, and 15 of each 28-day cycle. The primary objectives were to evaluate safety and tolerability, characterize dose-limiting toxicities (DLTs), and determine the recommended phase II dose (RP2D) of PF-04136309. Results In all, 21 patients received PF-04136309 at a starting dose of 500 mg or 750 mg BID. The RP2D was identified to be 500 mg BID. Of 17 patients treated at the 500 mg BID starting dose, three (17.6%) experienced a total of four DLTs, including grade 3 dysesthesia, diarrhea, and hypokalemia and one event of grade 4 hypoxia. Relative to the small number of patients (n = 21), a high incidence (24%) of pulmonary toxicity was observed in this study. The objective response rate for 21 patients was 23.8% (95% confidence interval: 8.2–47.2%). Levels of CD14 + CCR2+ inflammatory monocytes (IM) decreased in the peripheral blood, but did not accumulate in the bone marrow. Conclusions PF-04136309 in combination with nab-paclitaxel plus gemcitabine had a safety profile that raises concern for synergistic pulmonary toxicity and did not show an efficacy signal above nab-paclitaxel and gemcitabine. ClinicalTrials.gov identifier: NCT02732938." @default.
• W2959661609 created "2019-07-23" @default.
• W2959661609 creator A5011690090 @default.
• W2959661609 creator A5016800598 @default.
• W2959661609 creator A5018551530 @default.
• W2959661609 creator A5029168905 @default.
• W2959661609 creator A5032854284 @default.
• W2959661609 creator A5043592127 @default.
• W2959661609 creator A5043693897 @default.
• W2959661609 creator A5047496278 @default.
• W2959661609 creator A5052493398 @default.
• W2959661609 creator A5053776262 @default.
• W2959661609 creator A5057803141 @default.
• W2959661609 creator A5060044072 @default.
• W2959661609 creator A5070720153 @default.
• W2959661609 creator A5071193838 @default.
• W2959661609 creator A5074460989 @default.
• W2959661609 date "2019-07-12" @default.
• W2959661609 modified "2023-10-15" @default.
• W2959661609 title "Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma" @default.
• W2959661609 cites W1627927828 @default.
• W2959661609 cites W1790626605 @default.
• W2959661609 cites W1932486448 @default.
• W2959661609 cites W1968812902 @default.
• W2959661609 cites W1969004313 @default.
• W2959661609 cites W2004150448 @default.
• W2959661609 cites W2011627030 @default.
• W2959661609 cites W2011996641 @default.
• W2959661609 cites W2021268612 @default.
• W2959661609 cites W2038918212 @default.
• W2959661609 cites W2061159965 @default.
• W2959661609 cites W2068696687 @default.
• W2959661609 cites W2110271242 @default.
• W2959661609 cites W2140109386 @default.
• W2959661609 cites W2151253787 @default.
• W2959661609 cites W2157269800 @default.
• W2959661609 cites W2157612047 @default.
• W2959661609 cites W2163825883 @default.
• W2959661609 cites W2165064029 @default.
• W2959661609 cites W2165480504 @default.
• W2959661609 cites W2166760323 @default.
• W2959661609 cites W2168428587 @default.
• W2959661609 cites W2170202192 @default.
• W2959661609 cites W2341289486 @default.
• W2959661609 cites W2683486796 @default.
• W2959661609 cites W2772548919 @default.
• W2959661609 cites W2807847867 @default.
• W2959661609 cites W4244578979 @default.
• W2959661609 cites W4253861989 @default.
• W2959661609 doi "https://doi.org/10.1007/s10637-019-00830-3" @default.
• W2959661609 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7211198" @default.
• W2959661609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31297636" @default.
• W2959661609 hasPublicationYear "2019" @default.
• W2959661609 type Work @default.
• W2959661609 sameAs 2959661609 @default.
• W2959661609 citedByCount "93" @default.
• W2959661609 countsByYear W29596616092019 @default.
• W2959661609 countsByYear W29596616092020 @default.
• W2959661609 countsByYear W29596616092021 @default.
• W2959661609 countsByYear W29596616092022 @default.
• W2959661609 countsByYear W29596616092023 @default.
• W2959661609 crossrefType "journal-article" @default.
• W2959661609 hasAuthorship W2959661609A5011690090 @default.
• W2959661609 hasAuthorship W2959661609A5016800598 @default.
• W2959661609 hasAuthorship W2959661609A5018551530 @default.
• W2959661609 hasAuthorship W2959661609A5029168905 @default.
• W2959661609 hasAuthorship W2959661609A5032854284 @default.
• W2959661609 hasAuthorship W2959661609A5043592127 @default.
• W2959661609 hasAuthorship W2959661609A5043693897 @default.
• W2959661609 hasAuthorship W2959661609A5047496278 @default.
• W2959661609 hasAuthorship W2959661609A5052493398 @default.
• W2959661609 hasAuthorship W2959661609A5053776262 @default.
• W2959661609 hasAuthorship W2959661609A5057803141 @default.
• W2959661609 hasAuthorship W2959661609A5060044072 @default.
• W2959661609 hasAuthorship W2959661609A5070720153 @default.
• W2959661609 hasAuthorship W2959661609A5071193838 @default.
• W2959661609 hasAuthorship W2959661609A5074460989 @default.
• W2959661609 hasBestOaLocation W29596616091 @default.
• W2959661609 hasConcept C126322002 @default.
• W2959661609 hasConcept C143998085 @default.
• W2959661609 hasConcept C197934379 @default.
• W2959661609 hasConcept C2776694085 @default.
• W2959661609 hasConcept C2777063308 @default.
• W2959661609 hasConcept C2778375690 @default.
• W2959661609 hasConcept C2780258809 @default.
• W2959661609 hasConcept C29730261 @default.
• W2959661609 hasConcept C71924100 @default.
• W2959661609 hasConcept C90924648 @default.
• W2959661609 hasConcept C98274493 @default.
• W2959661609 hasConceptScore W2959661609C126322002 @default.
• W2959661609 hasConceptScore W2959661609C143998085 @default.
• W2959661609 hasConceptScore W2959661609C197934379 @default.
• W2959661609 hasConceptScore W2959661609C2776694085 @default.
• W2959661609 hasConceptScore W2959661609C2777063308 @default.
• W2959661609 hasConceptScore W2959661609C2778375690 @default.
• W2959661609 hasConceptScore W2959661609C2780258809 @default.
• W2959661609 hasConceptScore W2959661609C29730261 @default.
• W2959661609 hasConceptScore W2959661609C71924100 @default.

• next